Biogen returns gene therapies to AGTC on lack of clinical activity

Applied Genetic Technologies Corp. (NASDAQ:AGTC) said late Dec. 12 that Biogen Inc. (NASDAQ:BIIB) terminated the companies’ gene therapy collaboration, leaving behind a partnership originally established to help Biogen build its gene therapy expertise. AGTC was down $3.09 (47%) to $3.47 on Dec. 13.

Biogen made the decision to end the partnership after AGTC reported interim

Read the full 549 word article

How to gain access

Continue reading with a
two-week free trial.